American Well: 2027 Share Price Catalysts From Government Contract Wins

American Well is rated Buy, with shares up 158% year to date but still valued at about 1x forward sales. Imminent DHA and VA contract awards are cited as potential drivers of revenue and EBITDA growth by 2027, while the company continues to face revenue declines. AMWL guided for positive EBITDA and operating cash flow by 4Q26, supported by cost cuts and platform expansion.

Analysis

The key underwriting question is whether prospective DHA/VA work converts into durable, high-quality revenue—not whether awards are announced. Contract size, start dates, renewal terms, implementation costs, and contribution margin determine whether awards can offset the existing revenue trend; headline bookings alone may not support the projected EBITDA inflection. Government procurement and deployment can slip, while customer concentration could make quarterly results lumpy. Any benefit to Amwell would also validate virtual-care demand for competitors such as Teladoc, but does not establish that they lose share.

Near term, the sharp YTD rerating raises the risk that an award announcement is already partly discounted; the low sales multiple is not a floor if revenue keeps contracting. Over 1–3 months, verify award documentation and the company’s reported contract value, timing, and economics. Over 6–18 months, test whether growth is recurring and whether EBITDA improvement translates into operating cash flow rather than relying mainly on cost reductions. The contrarian risk is treating guidance as a forecast: absent award-level economics and stabilization in core revenue, the expected 2027 growth may be too early to underwrite.

Key Decisions for Investors

• Do not chase AMWL solely on anticipated awards. Treat the DHA/VA catalysts as unconfirmed until award scope, funding, and expected revenue timing are disclosed.
• Watch for a risk-defined long entry after confirmation, contingent on evidence that contract contribution can offset revenue declines. Reassess if awards slip or management does not provide measurable implementation and revenue milestones.
• Track quarterly revenue trends, operating cash flow, and the bridge from cost actions to EBITDA. A continued revenue decline or cash-flow deterioration despite announced wins would falsify the turnaround thesis.
• Avoid a TDOC pair trade without evidence of share displacement; government contract wins could expand the category rather than transfer revenue from competitors.